Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-HAV in Thai Children Lacking Protective Antibodies After L-HAV
NCT06978621Phase 3Active, not recruiting
- Sponsor
- Chiang Mai University
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hepatitis A vaccine inactivated in hepatitis A (HAV), sponsored by Chiang Mai University. Primary endpoints: Anti-HAV immunoglobulin G (IgG) seropositivity rate at 4 weeks and Incidence of adverse events following I-HAV vaccination at 4 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
hepatitis A vaccine inactivated
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on NCT06978621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06978621.